



SEPTEMBER 6-7, 2013 PISA
PALAZZO BLU
AUDITORIUM

CONFERENCE REGISTRATION

€ 375,00 + VAT 21%

Registration fee includes: conference kit, admission to all the scientific sessions, lunch and coffee breaks. It is possible to register online on the Official Site: <http://www.ipadcongress.com>

CONFERENCE VENUE

PALAZZO BLU

AUDITORIUM

Lungarno Gambacorti, 9

56125 PISA - ITALY

www.palazzoblu.org



OFFICIAL LANGUAGE

English is the official language of the Conference. No simultaneous translation will be provided.

CONTINUING MEDICAL EDUCATIONS (CME)

Italian CME credits will be requested.

Supported by unrestricted educational grants by



Organizing Secretariat



First Class S.r.l. Meetings and Conferences

Viale Italia, 173 - 57127 Livorno - Via Malasoma, 14/16 - 56121 Pisa - Italy - Ph: +39 0586 84 98 11 - Email: ipadcongress@fclassevents.com

WEBSITE <http://www.ipadcongress.com>



INTERNATIONAL CONFERENCE
ON NEW THERAPIES FOR PARKINSON
AND ALZHEIMER DISEASE

FACULTY

Giovanni Abbruzzese (Genoa)
Angelo Antonini (Padua)
Paolo Barone (Salerno)
Nicoletta Berardi (Pisa - Florence)
Fabio Blandini (Pavia)
Carlo Caltagirone (Rome)
Roberto Ceravolo (Pisa)
Anna Colzi (Bruxelles)
Giovanni Umberto Corsini (Pisa)
Mirco Cosottini (Pisa)
Grazia Dell'Agnello (Florence)
Ruggero Fariello (Lugano)
Antonio Federico (Siena)
Daniela Galimberti (Milan)
Leonardo Lopiano (Turin)
Andres Lozano (Toronto)
Marco Mainardi (Pisa)
Eldad Melamed (Tel Aviv)
Micaela Morelli (Cagliari)
Massimo Musicco (Rome)
Alessandro Padovani (Brescia)
Pasquale Palumbo (Prato)
Lucilla Parnetti (Perugia)
Nicola Pavese (London)
Marina Picillo (Salerno)
Gilberto Pizzolato (Trieste)
Werner Poewe (Innsbruck)
Michael J. Pontecorvo (Indianapolis)
Leandro Provinciali (Ancona)
J. Martin Rabey (Tel Aviv)
Olivier Rascol (Toulouse)
Elio Scarpini (Milan)
Marco Scarselli (Pisa)
Anthony Schapira (London)
Philip Scheltens (Amsterdam)
Orazio Schillaci (Rome)
Gabriele Siciliano (Pisa)
Fabrizio Stocchi (Rome)
Renato Turrini (Milan)
Duccio Volterrani (Pisa)

The 1st International Conference on New Therapies for Parkinson and Alzheimer Disease (IPAD)

will take place in Pisa on September 6 and 7, 2013: this meeting among experts of neurodegenerative diseases coming from the academic world, hospital centres and pharmaceutical industry, will focus on the new possibilities of preclinical diagnosis of motor and cognitive disorders, and on the more innovative pharmacological and non-pharmacological therapies. The results of phase 2 and phase 3 clinical trials will be evaluated and discussed, as well as on-going studies and the expected outcomes. New drugs' pipeline, non-pharmacological therapies, perspectives on biomarkers and on future diagnostic-therapeutic scenario will complete the program of this highly condensed meeting, that in the future will be repeated alternatively in Pisa and Florence with the aim of becoming a reference mark on novelties in the field.

Ubaldo Bonuccelli - Sandro Sorbi
Congress Presidents

INTERNATIONAL BOARD

Giovanni Abbruzzese (Genoa) - Angelo Antonini (Padua) - Paolo Barone (Salerno)
Carlo Caltagirone (Rome) - Anna Colzi (Bruxelles) - Bruno Dubois (Paris)
Murat Emre (Istanbul) - Ruggero Fariello (Lugano) - Harald-Jurgen Hampel (Munich)
Eldad Melamed (Tel Aviv) - Alessandro Padovani (Brescia) - Nicola Pavese (London)
Werner Poewe (Innsbruck) - J. Martin Rabey (Tel Aviv) - Anthony Schapira (London)
Philip Scheltens (Amsterdam) - Fabrizio Stocchi (Rome) - Renato Turrini (Milan)

LOCAL ORGANIZING COMMITTEE

Roberto Ceravolo (Pisa)
Laura Bracco (Florence)
Filippo Giorgi (Pisa)
Benedetta Nacmias (Florence)
Gloria Tognoni (Pisa)

Friday September 6

Registration 08.15
08.45 Welcome of the Mayor of Pisa
Marco Filippeschi

Session I 09.00 - 11.00
New therapies and mechanisms of disease
Chairmen: *Giovanni U. Corsini - Ubaldo Bonuccelli - Sandro Sorbi*
Animal models of Parkinson disease - *Fabio Blandini*
Animal models of Alzheimer disease - *Marco Mainardi*
Pathogenesis of Alzheimer disease and hints for new drugs
Daniela Galimberti
Pathogenesis of Parkinson disease and hints for new drugs
Anthony Schapira

Coffee Break
Session II 11.30 - 13.00
Biomarkers for detection, diagnosis and progression of disease
Chairmen: *Orazio Schillaci - Duccio Volterrani*
Parkinson disease overview - *Paolo Barone / Marina Picillo*
CSF biomarkers in neurodegenerative disorders - *Lucilla Parnetti*
Molecular imaging of neurodegenerative disorders
Michael J. Pontecorvo/Grazia Dell'Agnello

Session V 09.00 - 11.00
New trials and new drugs
Chairmen: *Leonardo Lopiano - Gilberto Pizzolato - Roberto Ceravolo*
Parkinson disease - *Olivier Rascol*
Alzheimer disease - *Philip Scheltens*
MAO B Inhibitors for Alzheimer and Parkinson disease
Fabrizio Stocchi
Adenosine antagonists: from basic research to the clinics
Micaela Morelli

11.00 - 11.30 **Coffee Break**

Lunch

Session III 14.00 - 16.00
Early recognition and treatment of preclinical and advanced stages of disease
Chairmen: *Leandro Provinciali - Carlo Caltagirone - Pasquale Palumbo*
Prodromal Alzheimer disease - *Alessandro Padovani*
Prodromal Parkinson disease - *Werner Poewe*
Motor/Behavioral complications in Parkinson disease - *Angelo Antonini*
Behavioral complications in Alzheimer disease - *Massimo Musicco*

Coffee Break

Session IV 16.30 - 18.30
Non Pharmacological Therapies
Chairmen: *Elio Scarpini - Antonio Federico - Gabriele Siciliano*
MCI: The Train the Brain study - *Nicoletta Berardi*
Co-utilization of rTMS and cognitive training for the treatment of Alzheimer dementia. A new non-invasive tool - *J. Martin Rabey*
Novelties on DBS for parkinsonism and dementia - *Andres Lozano*
Stem cells - *Eldad Melamed*

Saturday September 7

Session VI 11:30 - 13:30
ROUND TABLE Toward a closer collaboration between Academy and Industry
Chairmen: *Giovanni Abbruzzese - Mirco Cosottini - Ruggero Fariello*
Molecular Imaging in Parkinson disease - *Nicola Pavese*
Drug development trajectories in PD - *Anna Colzi*
Innovative drugs for AD and PD - *Renato Turrini*
Old and new drugs for neurodegenerative disorders: role of G protein-coupled receptors - *Marco Scarselli*
Concluding remarks - *Ruggero Fariello*